• Used as a predictive biomarker, the first-of-its-kind VENTANA MMR RxDx Panel helps identify cancer patients eligible for treatment with certain precision oncology therapies
  • By evaluating a panel of MMR proteins in tumours, the test provides clinicians with a standardised testing option to determine mismatch repair (MMR) status
  • This IVDR approval expands the companion diagnostic's label to include five cancer types and six indications